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Abstract: The application of ω-transaminase biocatalysts for the synthesis of optically pure 
chiral amines presents a number of challenges, including difficulties associated with 
displacing the challenging reaction equilibria. Herein, we report a highly effective approach 
using low equivalents of the novel diamine donor, cadaverine, which enables high 
conversions of challenging substrates to the corresponding chiral amines in excellent ee. This 
approach paves the way for the design of self-sufficient fermentation processes combining 
transaminase biotransformations with existing strategies for cadaverine production via 
decarboxylation of endogenous lysine.  
Chiral amines are prevalent in active pharmaceutical ingredients (APIs) and frequently 
feature as functional handles in widely used chemical building blocks.
1
 However, cost 
effective and sustainable access to optically pure derivatives continues to present a significant 
challenge for the pharmaceutical and chemical industries. In recent years, biocatalysis has 
emerged as a competitive and sustainable technology for the production of high-value 
chemicals.
2
 There has been a notable surge in the discovery and development of novel 
biocatalysts and biocatalytic processes for the preparation of optically pure amines, including 
those involving amine oxidases,
3
 ammonia lyases,
4
 imine reductases,
5
 amine dehydrogenases
6
 
and ω-transaminases (ω-TAs).3d,7 
ω-TAs in particular are emerging as extremely promising catalysts for chiral amine synthesis, 
starting from readily available prochiral ketones. These pyridoxal-5’-phosphate (PLP)-
dependent proteins are part of the aminotransferase class of enzyme (EC 2.6.1.18) and rely on 
a sacrificial amine donor to mediate the reversible conversion of structurally diverse ketones 
to the corresponding chiral primary amines.
8
 The development of a transaminase-catalyzed 
manufacturing route to the blockbuster antidiabetic drug sitagliptin, using a heavily 
engineered (R)-selective ω-TA, highlights the high level of interest in this enzyme family.7a 
However, despite the enormous synthetic potential of these biocatalysts, there remain limited 
examples of their application in industry. Challenges associated with overcoming 
unfavourable reaction equilibria as well as a restricted substrate scope has contributed to the 
relatively slow uptake of these biocatalysts in both academia and industry.  
Biotransformations employing ω-TAs 
typically involve the use of a large 
excess of isopropylamine (IPA) as a 
low-cost donor combined with in-situ 
evaporation of the acetone by-product 
to displace reaction equilibria towards 
product formation.
7a
 However, to obtain 
the low concentrations of acetone 
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required to achieve high conversions presents a significant technical challenge. In addition, 
this methodology cannot be successfully applied for the conversion of ketones with 
particularly challenging positions of equilibria.
9
 Alternative methods employed to displace 
reaction equilibria involve combinations of expensive enzymes, which function to remove the 
by-product and recycle costly co-factor.
3d,7b-c,10
 We have recently reported an extremely 
efficient strategy, which allows high conversions to be obtained using only 1.0 equivalent of 
the ‘smart’ diamine donor, o-xylylenediamine.11 The success of this approach can be 
attributed to spontaneous cyclization, tautomerization and irreversible polymerization of the 
by-product, which prevents the reverse reaction from compromising conversion. However, in 
addition to the relatively high cost of o-xylylenediamine (compared to IPA), the formation of 
coloured polymeric by-products has the potential to complicate downstream processing and 
product purification and therefore there remains considerable demand for the discovery of 
alternative ‘smart’ amine donors. In conjunction with effectively displacing challenging 
reaction equilibria, these new smart donors should be derived from bulk chemicals in order to 
be suitable for industrial scale chiral amine production.  
Diamines 1-6 (Scheme 1 (a)) were selected for initial evaluation, as the aminoaldehyde by-
products of these donors have the potential to dimerize or cyclise in a similar manner to o-
xylylenediamine, but are not expected to lead to the formation of insoluble polymers (Scheme 
1 (b)). A key challenge was to identify an ω-TA biocatalyst capable of accepting these 
diamines to enable their suitability as amine donors to be evaluated.  Importantly, this ω-TA 
must also have broad substrate scope towards structurally diverse ketones. 
 
 
 
Scheme 1. (a) Amine donors 1-6 screened with commercial enzymes and (b) predicted dimerization or 
cyclization of the by-products. (i) The aminoaldehyde by-products of 1 and 2 have the potential to undergo 
dimerization followed by spontaneous and irreversible oxidation to the pyrazine. (ii) The by-products of 
diamines 3-5 are expected to cyclize to the corresponding pyrroline or tetrahydropyridine and undergo further 
trimerization. 
 
 
While there are examples of diamino- and poly aminotransferases that accept similar amine 
donors,
12
 these enzymes suffer from an extremely narrow ketone substrate scope, which is 
thus far limited to alpha-keto acids. In contrast, commercially available ω-TAs from Codexis 
offer an extremely broad substrate scope and have been engineered for increased stability, 
making them the biocatalysts of choice in both academic and industrial laboratories. 
Therefore, our initial screen focused on evaluating twelve optimized Codexis biocatalysts
13
 
for their ability to utilize diamines 1-6. This preliminary screen, with 1.0 equivalent of donors 
1-6 and acetophenone as the acceptor, revealed donors 4 and 5 allowed significant conversion 
of the ketone to the corresponding chiral amine using (S)-selective ATA256 at pH 8.5 
(preliminary data not shown). Having identified ATA256 as a suitable biocatalyst, the 
conversion of acetophenone to MBA was monitored at a range of pH values using both 
diamine 4 and IPA as the amine donor (Figure 1). Despite this commercial enzyme being 
specifically engineered to accept high concentrations of IPA, cadaverine (also referred to as 
1,5-DAP) outperformed this donor across all three pH ranges tested. With both donors, 
increasing the reaction pH resulted in higher conversions. Significantly, only modest 
enhancements in conversions with increasing pH were obtained using the standard IPA 
donor. In contrast, conversions with cadaverine increased dramatically upon variation of pH 
from 9 to 10.9 (a more detailed discussion of the effect of pH is given below).  
 
 
 
Figure 1. pH-profile for the conversion of acetophenone to (S)-MBA using 3 equivalents of  IPA and 1,5-DAP 
as the amine donors. Conversions are reported after 48 hours. The values given are the mean of 2-3 repeats and 
the error bars represent the upper and lower limits of conversions obtained for individual reactions. 
 
 
Having established the optimum pH for performing these reactions, ATA256 was screened 
with ketones 7-9 and amine donors 4 and 5 (Table 1). In each case, the conversions were 
compared to those achieved using IPA as the amine donor. The ketone substrates (7-9) were 
rationally selected to allow the efficiency of these diamine donors to be evaluated in 
combination with progressively challenging substrates. Biocatalytic amination of 7-9 
becomes successively more challenging due to increasingly unfavourable positions of 
thermodynamic equilibria, as determined previously with alternative amine donors.
11
  
Using only 1.5 equivalents of diamine 4, essentially complete conversion (96%) of 4-
fluorophenylacetone 7 to (S)-4-fluoroamphetamine was achieved. Under the same conditions, 
a modest conversion of  69% was observed using IPA.  
Acetophenone is routinely used as a benchmark substrate in ω-TA biotransformations. An 
impressive conversion of 94% was achieved for this aromatic ketone with only 3.0 
equivalents of diamine 4, while  under the same conditions, IPA enabled only a modest 
conversion of 44%.  
 
Table 1. Conversion of 7-9 to the corresponding amines using ATA256 and diamines 4, 5 and IPA.   
 
 
Entry Acceptor Amine 
donor 
Equiv. Conv. ee 
[%] 
1 7 IPA 3.0 79% >99 (S) 
2 7 IPA 1.5 69% >99 (S) 
3 8 IPA 3.0 44% >99 (S) 
4 9 IPA 3.0 15% >99 (S) 
5 7 4 3.0 98% >99 (S) 
6 7 4 1.5 96% >99 (S) 
7 8 4 3.0 94% >99 (S) 
8 9 4 3.0 57% >99 (S) 
9 7 5 3.0 81% >99 (S) 
10 8 5 3.0 91% >99 (S) 
11 9 5 3.0 57% >99 (S) 
 
The ketone concentration was 20mM. Conversions are calculated from the mean of 3-5 replicates. ee values 
were measured by GC-FID using a chiral column (see supporting information). 
 
 
The conversion of 1-indanone 9 to aminoindane is known to be particularly challenging due 
to the extremely unfavourable position of equilibria associated with this transformation. We 
recently reported that 1.5 eq of o-xylylenedimaine was sufficient to achieve a 73% 
conversion to the corresponding chiral amine.
11
 In the same study we reported that a modest 
conversion (21%) was achieved using 10 eq of alanine and the widely used lactate 
dehydrogenase/glucose dehydrogenase pyruvate removal system. Using only 3.0 eq of 1,5-
DAP, a 54% conversion of 9 to (S)-(+)-1-aminoindane is achieved demonstrating the ability 
of this diamine donor to displace the equilibria of extremely challenging substrates. Under the 
same conditions, IPA performed poorly as expected, reaching only 15% conversion after 48 
hours. The conversions with substrates 7-9 obtained with the related diamine 5 were broadly 
comparable to those achieved with 1,5-DAP (Entries 9-11).  
The conversion of acetophenone 8 to MBA was subsequently carried out on a preparative 
scale (Scheme 2 (b)) to demonstrate the suitability of this system for performing preparative 
scale transformations and to allow by-product characterization. We anticipated that the fate of 
the initially formed cyclic imine by-product may provide a rationale for the dramatic increase 
in conversions with increasing pH. To aid by-product characterization, imine 12 was prepared 
synthetically following a literature procedure
14
 (Scheme 2 (a)). The symmetrical product 13 
was initially isolated exclusively and subsequently converted to isotripiperidine 14.
14
 The 
unsymmetrical trimer was characterised by mass spectrometry and NMR
14,15
 and the x-ray 
crystal structure of the molecule was solved (Scheme 2 (c)). Only trimer 14 was observed in 
the preparative scale biotransformation (Scheme 2 (b)) by both GC and NMR (see supporting 
information Figure S1 for NMR overlay) and could be seperated from the chiral amine 
product by filtering through silica. This result is in line with literature reports that this trimer 
is stable at pH10
16
 and may rationalise why a higher reaction pH leads to increased 
conversions.  
 
 
 
 
 
Scheme 2. a) Synthesis of tripiperidine 13 and unsymmetrical isotripiperidine 14.
14
 (i) N-Chlorosuccinimide, 
Et2O, 0ºC, 2 h; (ii) EtOH, KOH, reflux, 2 h, 68% over two steps; (iii) recrystallized in acetone, -20 ºC, 5 days. 
b) Preparative-scale biotransformation of acetophenone 8 to (S)-MBA using ATA256 and 1,5-DAP 4. c) Crystal 
structure of isotripiperidine 14. 
 
 
To determine whether the formation of trimer 14 is reversible under biotransformation 
conditions and to further investigate the influence of pH on reaction equilibria, purified trimer 
14 was evaluated as an amine acceptor in combination with (S)-aminoindane 15 (i.e. the 
reverse process of entry 8, Table 1), at a range of pH values (pH 8-10.9) (Table 2). Table 2 
shows that at pH 8, (S)-aminoindane 15 is readily converted to indanone 9 (68%) while at 
higher pH values, this conversion is much less efficient. At pH 10.9 (the optimal reaction 
conditions employed in this study) a modest conversion of 14% was achieved. These results 
suggest that formation of unsymmetrical trimer 14 is favoured at higher pH and that trimer 
formation contributes to the displacement of the thermodynamic equilibrium towards the 
desired amine products.   
 
 
Table 2. Conversion of amine acceptor 14 to cadaverine 4 using ATA256 and (S)-aminoindane over pH range 
8-10.9.  
 
 
 
Entry ATA Amine donor Acceptor pH Conv. 
1 256  15 14 8.0 68% 
2 256 15 14 9.0 57% 
3 256 15 14 10 28% 
4 256 15 14 10.9 14% 
Conversions are based on the formation of ketone 9 from (S)-aminoindane 15, monitored by GC-FID. 
 
 
 
In summary, we have identified an ω-TA that has broad acceptor substrate scope and 
is capable of using the bulk diamine cadaverine as an amine donor. This new 
generation ‘smart’ diamine is highly effective at displacing challenging reaction 
equilibria, enabling high conversions to the desired optically pure chiral amine 
products in the absence of by-product removal systems. The success of this donor can 
be attributed to a spontaneous dehydrative cyclization/trimerization of the reaction by-
product following transamination. In all cases, cadaverine significantly outperforms 
the industry standard amine donor, isopropylamine, and therefore this work represents 
an important proof-of-concept study. Future efforts will focus on the identification of 
ω-TAs that accept alternative bulk diamines (including 1,4-diaminobutane or 
putrescine), performing reactions at significantly higher substrate concerntrations and 
exploring the potential of self-sufficient fermentation processes whereby the 
cadaverine donor is produced biosynthetically via lysine decarboxylation.  
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